Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis
Authors:
- Shiza ZainabSZShiza Zainab
- Laiba ZaheerLZLaiba Zaheer
- Aamna Raheel SheikhASAamna Raheel Sheikh
- Muhammad Salman KhalidMKMuhammad Salman Khalid
- Muhammad Zayd ArshadMAMuhammad Zayd Arshad
- Amena KhatoonAKAmena Khatoon
- Nawal ZahraNZNawal Zahra
- Eshan AhmedEAEshan Ahmed
- Eman ZakirEZEman Zakir
- Eshal FatimaEFEshal Fatima
- Asher TariqATAsher Tariq
- Kalsoom AbbasKAKalsoom Abbas
- 29 July 2026
- journal article
- review article
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (10) , 2605-2615
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology populationJournal of Medical Economics, 2025
- The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-AnalysisCalcified Tissue International, 2023
- Pharmacists’ experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods studyJournal of the American Pharmacists Association, 2021
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionThe Lancet Diabetes & Endocrinology, 2017
- Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based surveymAbs, 2016
- Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumabNature Reviews Drug Discovery, 2012
- Effects of denosumab on bone turnover markers in postmenopausal osteoporosisJournal of Bone and Mineral Research, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Denosumab in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2006